Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Down 45.2% in December

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOAGet Free Report) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totalling 37,100 shares, a decline of 45.2% from the December 15th total of 67,700 shares. Based on an average daily trading volume, of 307,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.8% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOAFree Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Trading Up 1.5 %

Shares of NASDAQ:SNOA traded up $0.04 during midday trading on Thursday, reaching $2.66. 53,750 shares of the company were exchanged, compared to its average volume of 43,035. The stock has a market cap of $3.56 million, a PE ratio of -0.53 and a beta of 1.41. The business’s fifty day moving average is $2.73 and its two-hundred day moving average is $2.12. Sonoma Pharmaceuticals has a one year low of $2.44 and a one year high of $9.37.

About Sonoma Pharmaceuticals

(Get Free Report)

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.

Read More

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.